Infectious complications associated with the use of immune checkpoint inhibitors in oncology
WANG Qiqi, LI Ruoyu, LIU Wei
Department of Dermatology and Venereology, Peking University First Hospital; National Clinical Research Center for Skin and Immune Diseases; Research Center for Medical Mycology, Peking University; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, China
Abstract：In recent years, the use of immune checkpoint inhibitors (ICI) for tumor immunotherapy has received widespread attention. The development of checkpoint blocking antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) has brought great hope for the treatment of melanoma and other tumors. There is no evidence that immune checkpoint inhibitors increase the risk of infection, but the upregulation of immune function leads to a series of immune-related adverse events (irAEs) which requires immunosuppressive therapy, and may lead to opportunistic infection. Cases of latent or chronic infection reactivation in the absence of irAEs have been reported. In this review, we focus on the phenomena, possible mechanisms and related prevention and treatment strategies of infectious complications associated with the use of immune checkpoint inhibitors in oncology.
王琦琦，李若瑜，刘伟. 肿瘤治疗中免疫检查点抑制剂相关的感染并发症[J]. 微生物与感染, 2021, 16(1): 50-56.
WANG Qiqi, LI Ruoyu, LIU Wei. Infectious complications associated with the use of immune checkpoint inhibitors in oncology. JOURNAL OF MICROBES AND INFECTIONS, 2021, 16(1): 50-56.
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara H, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies[J]. Semin Cancer Biol, 2015, 35 Suppl: S185-S98.
[2]
Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize[J]. Nature, 2018, 562(7725): 20-1.
[3]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-64.
[4]
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-70.
[5]
Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018, 8(9): 1069-86.
[6]
Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells[J]. Immunol Cell Biol, 2018, 96(1): 21-33.
[7]
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704.
[8]
Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance[J]. J Exp Med, 2009, 206(2): 421-34.
[9]
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LSK, Sansom DM. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4[J]. Science, 2011, 332(6029): 600-3.
[10]
Wang XB, Fan ZZ, Anton D, Vollenhoven AV, Ni ZH, Chen XF, Lefvert AK. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation[J]. BMC Immunol, 2011, 12: 21.
[11]
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-28.
[12]
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J]. N Engl J Med, 2015, 373(1): 23-34.
[13]
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma[J]. J Exp Med, 2003, 198(6): 851-62.
[14]
Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J]. Sci Signal, 2012, 5(230): ra46.
[15]
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800.
[16]
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J]. J Exp Med, 2009, 206(13): 3015-29.
[17]
Administration USFaDDF. Ipilimumab (Yervoy) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s108lbl.pdf
[18]
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 33(17): 1889-94.
[19]
Administration USFaDDF. Pembrolizumab (Keytruda) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s067lbl.pdf
[20]
Administration USFaDDF. Nivolumab (Opdivo) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s078lbl.pdf
[21]
Administration USFaDDF. Atezolizumab (Tecentriq) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s021lbl.pdf
[22]
Administration USFaDDF. Durvalumab (Imfinzi) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761069s018lbl.pdf
[23]
Administration USFaDDF. Avelumab (Bavencio) Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761049s006lbl.pdf
June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy?[J]. Nat Med, 2017, 23(5): 540-7.
[26]
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. Eur J Cancer, 2016, 54: 139-48.
[27]
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017, 28(3): 583-9.
[28]
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma[J]. Journal for immunotherapy of cancer, 2015, 3: 39.
[29]
Gozzi E, Rossi L, Angelini F, Leoni V, Trenta P, Cimino G, Tomao S. Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report[J]. Thorac Cancer, 2020, 11(5):1330-1333.
[30]
Ferguson I, Heberton M, Compton L, Keller J, Cornelius L. Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma[J]. JAAD Case Rep, 2019, 5(7): 580-1.
[31]
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet (London, England), 2016, 387(10031): 1909-20.
[32]
Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab[J]. J Immunother, 2015, 38(5): 212-5.
[33]
Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause pneumonia but spare antitumor immune control[J]. Oncoimmunology, 2015, 4(10): e1040218.
[34]
Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma[J]. Clin Infect Dis, 2016, 63(11): 1490-3.
[35]
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2020.[J]. J Natl Compr Canc Netw, 2020, 18: 230-241.
[36]
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities[J]. The Lancet Oncology, 2019, 20(1): e54-e64.
[37]
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(2): 123-35.
[38]
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA, Hansson J, Masucci G. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma[J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2017, 28(7): 1672-3.
[39]
Comito RR, Badu LA, Forcello N. Nivolumab-induced aplastic anemia: A case report and literature review[J]. J Oncol Pharm Pract, 2019, 25(1): 221-5.
[40]
Filetti M, Giusti R, Di Napoli A, Iacono D, Marchetti P. Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know[J]. Tumori, 2019, 105(6): NP48-NP51.
[41]
Delanoy N, Michot J-M, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Sa?ag P, Madonna E, Maerevoet M, Bout J-C, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin A-L, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study[J]. The Lancet Haematology, 2019, 6(1): e48-e57.
[42]
Fujita K, Kim YH, Kanai O, Yoshida H, Mio T, Hirai T. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy[J]. Respir Med, 2019, 146: 66-70.
[43]
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017, 13(4): 195-207.
[44]
Lee JJ, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma[J]. Acta Oncol, 2016, 55(4): 519-20.
[45]
Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment[J]. Clin Microbiol Infect, 2018, 24(3): 216-8.
[46]
Chu YC, Fang KC, Chen HC, Yeh YC, Tseng CE, Chou TY, Lai CL. Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma[J]. J Thorac Oncol, 2017, 12(8): e111-e4.
[47]
Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR, Jr. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis[J]. Proc Natl Acad Sci U S A, 2010, 107(30): 13402-7.
[48]
Uchida N, Fujita K, Nakatani K, Mio T. Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab[J]. Respirol Case Rep, 2018, 6(2): e00289.
2021, Vol. 16 
